article Open AccessTop 1% cited

Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K

Cancer Cell · 2010 · Vol. 18(6) · pp. 683–695

Jessie Villanueva(The Wistar Institute)Adina Vultur(The Wistar Institute)John Tayu Lee(The Wistar Institute)Rajasekharan Somasundaram(The Wistar Institute)Mizuho Fukunaga‐Kalabis(The Wistar Institute)Angela K. Cipolla(The Wistar Institute)Bradley Wubbenhorst(University of Pennsylvania)Xiaowei Xu(University of Pennsylvania)Phyllis A. Gimotty(University of Pennsylvania)Damien Kee(Peter MacCallum Cancer Centre)Ademi Santiago-Walker(The Wistar Institute)Richard Letrero(University of Pennsylvania)Kurt D’Andrea(University of Pennsylvania)Anitha Pushparajan(University of Pennsylvania)James E. Hayden(The Wistar Institute)Kimberly Dahlman Brown(Vanderbilt University Medical Center)Sylvie Laquerre(GlaxoSmithKline (United States))Grant A. McArthur(Peter MacCallum Cancer Centre)Jeffrey A. Sosman(Vanderbilt University Medical Center)Katherine L. Nathanson(University of Pennsylvania)Meenhard Herlyn✉(The Wistar Institute)

View via DOI Full-text PDF

Melanoma and MAPK Pathways HER2/EGFR in Cancer Research Cytokine Signaling Pathways and InteractionsPI3K/AKT/mTOR pathwayKinaseMelanomaCancer researchMEK inhibitorMAPK/ERK pathwayBiologyChemistrySignal transductionCell biology

MeSH terms

Phosphoinositide-3 Kinase InhibitorsHumansMelanomaPhosphorylationReceptor, IGF Type 1Drug Resistance, NeoplasmPhosphatidylinositol 3-KinasesMitogen-Activated Protein Kinase KinasesMAP Kinase Signaling SystemCell Line, Tumorraf KinasesProto-Oncogene Proteins B-rafProto-Oncogene Proteins c-akt